http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20170021411-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0fd6fdb8cc439061143dc8a966303868 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-517 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-497 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-497 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-517 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-52 |
| filingDate | 2015-08-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_835ae28f41f9b2b4523d09ba8fa05611 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_20d96df2ef07dfdafb7f3191397a7c51 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_086bd642fbe57fc783b8919e7fa3e91e |
| publicationDate | 2017-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20170021411-A |
| titleOfInvention | Pharmaceutical composition for enhancing effect to doxorubicin and Photodynamic therapy against cancer comprising c-MET inhibitor |
| abstract | The present invention relates to a pharmaceutical composition for enhancing an anticancer effect of doxorubicin, which comprises a c-MET inhibitor as an active ingredient, and a pharmaceutical composition for enhancing the anticancer effect of a broad-band pharmacological treatment comprising a c-MET inhibitor as an active ingredient, PI3K inhibitor, and one or more selected from the group consisting of the c-MET inhibitor alone or a combination of c-MET inhibitor, PI3K inhibitor and a mixture thereof may be co-treated with doxorubicin in cancer cells or treated with cancer cells before PDT treatment , Intracellular doxorubicin accumulation and ROS levels are increased, accumulation of intracellular photosensitizer is increased, and cell death may be induced. Therefore, it is possible to prevent the resistance of cancer cells to doxorubicin or PDT treatment and to increase the sensitivity of doxorubicin or PDT to improve the efficiency of chemotherapy. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023121394-A1 |
| priorityDate | 2015-08-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 224.